176 related articles for article (PubMed ID: 19558190)
1. Informing disinvestment through cost-effectiveness modelling: is lack of data a surmountable barrier?
Karnon J; Carlton J; Czoski-Murray C; Smith K
Appl Health Econ Health Policy; 2009; 7(1):1-9. PubMed ID: 19558190
[TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness and cost-effectiveness of screening programmes for amblyopia and strabismus in children up to the age of 4-5 years: a systematic review and economic evaluation.
Carlton J; Karnon J; Czoski-Murray C; Smith KJ; Marr J
Health Technol Assess; 2008 Jun; 12(25):iii, xi-194. PubMed ID: 18513466
[TBL] [Abstract][Full Text] [Related]
3. The potential cost-effectiveness of amblyopia screening programs.
Rein DB; Wittenborn JS; Zhang X; Song M; Saaddine JB;
J Pediatr Ophthalmol Strabismus; 2012; 49(3):146-55; quiz 145, 156. PubMed ID: 21877675
[TBL] [Abstract][Full Text] [Related]
4. Sustainability in Health care by Allocating Resources Effectively (SHARE) 2: identifying opportunities for disinvestment in a local healthcare setting.
Harris C; Allen K; King R; Ramsey W; Kelly C; Thiagarajan M
BMC Health Serv Res; 2017 May; 17(1):328. PubMed ID: 28476159
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluations of vision screening to detect amblyopia and refractive errors in children: a systematic review.
Asare AO; Wong AMF; Maurer D; Kulandaivelu Y; Saunders N; Ungar WJ
Can J Public Health; 2022 Apr; 113(2):297-311. PubMed ID: 34755325
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility analysis of orthoptic screening in kindergarten: a Markov model based on data from Germany.
König HH; Barry JC
Pediatrics; 2004 Feb; 113(2):e95-108. PubMed ID: 14754978
[TBL] [Abstract][Full Text] [Related]
7. Breaking up is hard to do: why disinvestment in medical technology is harder than investment.
Haas M; Hall J; Viney R; Gallego G
Aust Health Rev; 2012 May; 36(2):148-52. PubMed ID: 22624634
[TBL] [Abstract][Full Text] [Related]
8. [Cost-effectiveness of screening for amblyopia].
Neubauer AS; Neubauer S
Klin Monbl Augenheilkd; 2005 Feb; 222(2):110-6. PubMed ID: 15719314
[TBL] [Abstract][Full Text] [Related]
9. Who does the numbers? The role of third-party technology assessment to inform health systems' decision-making about the funding of health technologies.
Barbieri M; Hawkins N; Sculpher M
Value Health; 2009; 12(2):193-201. PubMed ID: 18700865
[TBL] [Abstract][Full Text] [Related]
10. Case studies that illustrate disinvestment and resource allocation decision-making processes in health care: a systematic review.
Polisena J; Clifford T; Elshaug AG; Mitton C; Russell E; Skidmore B
Int J Technol Assess Health Care; 2013 Apr; 29(2):174-84. PubMed ID: 23514665
[TBL] [Abstract][Full Text] [Related]
11. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC; Blommestein HM; Riemsma R; Armstrong N; Clay FJ; Ross J; Worthy G; Severens J; Kleijnen J; Al MJ
Pharmacoeconomics; 2017 Dec; 35(12):1211-1221. PubMed ID: 28656543
[TBL] [Abstract][Full Text] [Related]
12. Preschool vision screening: a prospective comparative evaluation.
Bray LC; Clarke MP; Jarvis SN; Francis PM; Colver A
Eye (Lond); 1996; 10 ( Pt 6)():714-8. PubMed ID: 9091368
[TBL] [Abstract][Full Text] [Related]
13. A novel research design can aid disinvestment from existing health technologies with uncertain effectiveness, cost-effectiveness, and/or safety.
Haines T; O'Brien L; McDermott F; Markham D; Mitchell D; Watterson D; Skinner E
J Clin Epidemiol; 2014 Feb; 67(2):144-51. PubMed ID: 24275500
[TBL] [Abstract][Full Text] [Related]
14. NICE recommendations: why no disinvestment recommendations to offset investment decisions?
Hughes DA; Wood EM; Tuersley L
BMJ; 2015 May; 350():h2656. PubMed ID: 25989993
[No Abstract] [Full Text] [Related]
15. Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System.
Edney LC; Haji Ali Afzali H; Cheng TC; Karnon J
Pharmacoeconomics; 2018 Feb; 36(2):239-252. PubMed ID: 29273843
[TBL] [Abstract][Full Text] [Related]
16. Sustainability in Health care by Allocating Resources Effectively (SHARE) 10: operationalising disinvestment in a conceptual framework for resource allocation.
Harris C; Green S; Elshaug AG
BMC Health Serv Res; 2017 Sep; 17(1):632. PubMed ID: 28886740
[TBL] [Abstract][Full Text] [Related]
17. A Tale of Two Thresholds: A Framework for Prioritization within the Cancer Drugs Fund.
Leigh S; Granby P
Value Health; 2016; 19(5):567-76. PubMed ID: 27565274
[TBL] [Abstract][Full Text] [Related]
18. Health Technology Disinvestment in Singapore.
Lim BP; Heng BH; Tai HY; Tham L; Chua HC
Ann Acad Med Singap; 2018 Aug; 47(8):338-344. PubMed ID: 30242300
[TBL] [Abstract][Full Text] [Related]
19. Disinvestment in healthcare: an overview of HTA agencies and organizations activities at European level.
Calabrò GE; La Torre G; de Waure C; Villari P; Federici A; Ricciardi W; Specchia ML
BMC Health Serv Res; 2018 Mar; 18(1):148. PubMed ID: 29490647
[TBL] [Abstract][Full Text] [Related]
20. Generalisability in economic evaluation studies in healthcare: a review and case studies.
Sculpher MJ; Pang FS; Manca A; Drummond MF; Golder S; Urdahl H; Davies LM; Eastwood A
Health Technol Assess; 2004 Dec; 8(49):iii-iv, 1-192. PubMed ID: 15544708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
